Overview

A Study of Oral Vismodegib in Combination With Pirfenidone in Participants With Idiopathic Pulmonary Fibrosis

Status:
Completed
Trial end date:
2016-11-30
Target enrollment:
Participant gender:
Summary
This is a single arm, multicenter, open-label, Phase 1b study to evaluate the safety and tolerability of vismodegib in combination with pirfenidone in participants with idiopathic pulmonary fibrosis (IPF) currently being treated with pirfenidone.
Phase:
Phase 1
Details
Lead Sponsor:
Hoffmann-La Roche
Treatments:
Pirfenidone